Product Counsel

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN. Business Wire Published Oct 26, 2026 Second limited-edition WHOOP x SR_A collection brings "performance for life" to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. BOSTON - WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. Story continues below This advertisement has not loaded yet, but your article continues below. While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Top Stories Interested in more newsletters? Browse here. Performance extends beyond sport and competition. It is how we move, recover, adapt, and continue doing what we love. WHOOP helps people better understand their bodies so they can make smarter choices across sport, health, and life. Designed for changing states, Layer 2 brings SR_A's distinct architectural language to garments that combine tactile materials, considered construction, and technical requirements. The collection uses nature's terrain as both inspiration and proving ground, creating pieces designed to perform across environments. "I've always said our ambition with WHOOP is to create something that's either cool or invisible," said Will Ahmed, Founder and CEO of WHOOP. "Our partnership with Samuel Ross pushes that philosophy to the next level. PROJECT TERRAIN reflects the respect we've always had for great design and our belief that the technology you wear every day should be something you love wearing." "PROJECT TERRAIN is an expression of intensity and resilience, designed for those who embrace exploration, discipline and the pursuit of performance," said Samuel Ross MBE, Global Creative Director of WHOOP x SR_A. "Our second collection draws inspiration from the transition between dense urban environments and expansive rural landscapes, creating functional garments that adapt across all five zones of training. Combining exceptional technical fabrics, precision construction and refined silhouettes, the collection balances performance with everyday utility. At its core, PROJECT TERRAIN is about creating resilient, purposeful garments for those who push beyond their limits." PROJECT TERRAIN Layer 2 Collection The limited-edition Layer 2 collection includes two new band designs for WHOOP 5.0 and WHOOP MG, alongside a range of men's and women's apparel, outerwear, and accessories. Products range from $60 to $650, with WHOOP bands priced at $99. Collection Details WHOOP 5.0 and WHOOP MG Bands Story continues below This advertisement has not loaded yet, but your article continues below. ATLAS BAND - $99/ €99 / £69 [Colors: Cinder, Volta] Performance and Activewear 02 - NOMAD TECHNICAL PUFFER - $650/ €749 / £639 [Colors: Onyx, Solstice] 02 STRATA TECHNICAL JOGGER - $130/ €129/ £99 [Colors: Ash, Earth, Onyx] 02 -TERRAIN FITTED TEE - WOMEN - $100 / €99 / £69 [Colors: Onyx, Terra] 02 - TERRAIN FITTED TEE - MEN - $100 / €99 / £69 [Colors: Onyx, Terra] 02 - STRATA TECHNICAL SHORT - $110 / €119 / £89 [Colors: Ash, Earth, Onyx] 02 - SUMMIT SCULLY - $60 / €64 / £49 [Color: Onyx] 02 - FRAME PERFORMANCE BRA - $90 / €89 / £69 [Color: Terra] 02 - FRAME PERFORMANCE LEGGINGS - $130 / €129 / £99 [Color: Terra] "As wearable technology becomes increasingly integrated into how we live, the opportunity lies in rethinking how and where it is worn. Following the sell-out of our debut PROJECT TERRAIN collection, Layer 2 builds on WHOOP's Any-Wear(TM) technology to explore new sensor placements across technical garments, extending from performance apparel into outerwear and everyday wear. At SR_A, our thesis is to apply design thinking to the next evolution of wearable technology and changing ways of living, combining material innovation, functional utility and purposeful form to create products that move beyond conventional categories. PROJECT TERRAIN challenges conventional boundaries between technology, garment design and everyday life," said Yi Ng, co-founder and CEO of SR_A. To view images of the collection, visit the digital press kit here.About WHOOP WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and longevity. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Research shows that people who wear WHOOP daily log more than 90 additional minutes of exercise per week, get over two extra hours of sleep, and have 10% higher heart rate variability. Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $950 million in venture capital, ships to 56 countries, and operates in six languages. To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube. This advertisement has not loaded yet. This advertisement has not loaded yet, but your article continues below. About SR_A SR_A is a garment atelier fortifying the body. The atelier produces bespoke seasonal collections rooted in craft, innovation and utility, alongside distinct collaborations with industry leaders including LVMH group, Nike Inc & Apple Group. Headquartered in London, the atelier was co-founded by Samuel Ross MBE and his longtime business partner, Yi Ng in 2019. Well known for its considered ethos, rooted in the expression of architecture, cultural subversion, and deeply functional garments for living, SR_A's study of serving the human body has led to several patent filings and global recognition awards across fashion and design. SR_A's legacy retail partners include Dover Street Market & BIOTOP Japan. View source version on businesswire.com: This advertisement has not loaded yet. Quick Picks Ocean Maya Royale: Your adults-only beach retreat in Riviera Maya.Ocean Signature Resorts | Sponsored

In the presence of Theyab bin Mohamed bin Zayed, Department of Health - Abu Dhabi signs agreements to advance research in life sciences, personalised preventive health, and AI drug discovery. In the presence of His Highness Sheikh Theyab bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Development and Fallen Heroes' Affairs, the Department of Health - Abu Dhabi (DoH) has signed agreements with Isomorphic Labs, WHOOP, and Cleveland Clinic Abu Dhabi, and AstraZeneca. DoH and Isomorphic Labs announced the signing of an agreement to collaborate on AI-enabled drug discovery research and explore innovation frameworks for pre-clinical research. The agreement was signed at the Abu Dhabi Future Health Summit by Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, and Max Jaderberg, President of Isomorphic Labs. Under the agreement, the collaboration aims to develop a pre-clinical research roadmap for selected AI-enabled discovery projects over a 24-month period, with research conducted within Abu Dhabi's Trusted Research Environment. Isomorphic Labs has built a world-leading drug design engine (IsoDDE) comprised of foundational AI models to provide the predictive fidelity required to navigate novel biological systems with unprecedented accuracy. His Excellency Mansoor Ibrahim Al Mansoori, said: "Artificial intelligence is changing not only how quickly we discover new medicines, but how precisely we can target disease. Realising that potential requires more than technology. It requires rich clinical and genomic data, a research environment that can translate insight into discovery, and regulation that advances at the pace of science. "Abu Dhabi has built that foundation. Through the Emirati Genome Programme and our connected health system, we are opening new possibilities for more precise, personalised treatments. Our collaboration with Isomorphic Labs brings together expertise in AI drug discovery and Abu Dhabi's unique strengths to accelerate the development of treatments that can benefit patients here and globally." Mr Jaderberg said: "At Isomorphic Labs, we are reimagining the entire drug discovery process from first principles with AI. The collaboration marks a critical step forward in advancing AI-driven drug discovery. We have a shared commitment to scientific innovation, with the ultimate aim of accelerating delivery of medicines to patients globally." The collaboration reflects DoH's role in enabling the responsible use of predictive and generative AI in health research. It forms part of Abu Dhabi's intelligent life sciences strategy which connects population-scale genomic and health data, research infrastructure, and regulatory pathways to accelerate the development of new medicines in the emirate. Together, the parties aim to help accelerate AI-driven discovery research, as well as broaden the evidence base for future medicines, as Middle Eastern populations have been historically underrepresented in the genomic data behind drug discovery. Meanwhile, DoH and WHOOP announced a strategic research collaboration to explore the role of continuous health insights and coaching in preventive health. The research supports Abu Dhabi's shift from reacting to illness towards personalised prevention at scale. The agreement was also signed at the Abu Dhabi Future Health Summit 2026 by His Excellency Mansoor Ibrahim Al Mansoori, and Will Ahmed, Founder and CEO of WHOOP. The collaboration will consist of a phased research programme on heart and metabolic health, exploring how wearable technology can help people better understand their bodies and take a more informed, proactive approach to their health. WHOOP continuously senses an individual's key health indicators such as sleep, recovery, strain, stress, and cardiovascular health, providing context beyond a single measurement. The first, foundational study of the24-month programme aims to assess how this continuous data, alongside coaching from WHOOP, can affect key health markers like weight, waist circumference, heart rate, blood pressure, cholesterol, blood sugar, and sleep over a six-month period for adults with obesity and high blood pressure. The study's design and oversight will be supported by physicians in Abu Dhabi. Subsequent studies will explore how WHOOP can help reduce risk factors for heart and metabolic disease by supporting the behavioural changes required alongside treatment. The programme will generate novel, real-world evidence on the role wearable technology can play in preventive and cardiometabolic health. In line with Abu Dhabi's prevention-led health agenda, the collaboration brings the continuous health data of WHOOP into the emirate's intelligent health system to accelerate population health research and safely scale new models of care. His Excellency Mansoor Ibrahim Al Mansoori said: "Our bodies can signal changes long before we feel unwell. The earlier we recognise those signals, the more we can do to protect our health. Abu Dhabi has built an intelligent health system that uses AI to turn complex health data into meaningful, personalised insights. Our partnership with WHOOP will explore how data from wearables can be translated into practical, personalised guidance, helping people better understand their health and make lasting changes." Mr Ahmed said: "This is a landmark partnership for WHOOP and Abu Dhabi. We first began working in the UAE in 2016. Since then, hundreds of thousands of citizens and residents have come to trust WHOOP to support their health and performance goals. At WHOOP, we believe deeply in what continuous data insights and coaching can offer when applied to real health challenges. Abu Dhabi puts data at the heart of how it cares for people, and I'm incredibly proud to work alongside them to explore what's possible, and even more excited about what we can accomplish together." Research will follow data governance guidelines over data minimisation, transparent data processing and secure storage, in line with applicable regulations and international best practices. Meanwhile, DoH, Cleveland Clinic Abu Dhabi, and AstraZeneca have announced a new collaboration positioning Abu Dhabi as a priority location in AstraZeneca's global clinical trial network. The collaboration leverages the emirate's intelligent health system, advanced research infrastructure and enabling regulatory environment. The collaboration will explore the feasibility of up to 30 clinical trials in Abu Dhabi by 2030 across AstraZeneca's biopharmaceutical portfolio with a focus on cardiovascular, renal and metabolic (CVRM) diseases, which are leading causes of mortality in UAE. The collaboration could deliver an estimated AED180 million (US$50 million) investment into life sciences research in Abu Dhabi by 2030. The collaboration builds on Abu Dhabi's long-term partnership with AstraZeneca in research, genomics, and digital health. It brings together DoH's role in enabling clinical research and developing Abu Dhabi's intelligent life sciences ecosystem, Cleveland Clinic Abu Dhabi's clinical and research expertise, and AstraZeneca's global R&D capabilities. Drawing on Cleveland Clinic Abu Dhabi's research infrastructure, it aims to strengthen local research capacity and generate high-quality evidence relevant to the region's health needs. The first six trials are expected to begin at Cleveland Clinic Abu Dhabi by the end of 2026. His Excellency Mansoor Ibrahim Al Mansoori, said: "Abu Dhabi has built an intelligent health system where population scale data, research infrastructure, and clinical excellence translate into better health outcomes. This collaboration brings global clinical trials into this system, supporting our ambition to create a globally recognised environment for clinical research, and strengthens the evidence base to help ensure that new medicines are developed for the diversity of the world's patients." Dr Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said: "By combining Cleveland Clinic clinical expertise, the Department of Health - Abu Dhabi's infrastructure, and AstraZeneca's global research capabilities, we can accelerate clinical research, expand access to innovative treatments, and generate evidence that improves patient outcomes. Together, we are strengthening Abu Dhabi's position as a leader in clinical research, with benefits for patients across the globe." Mikhail Kosiborod, Senior Vice President, Late CVRM BioPharmaceutical R&D, AstraZeneca, said: "Clinical trials play a vital role in generating high-quality evidence that advances healthcare, providing patients with early access to promising new therapies and ensuring our data is generated in diverse, representative populations. This collaboration with the Department of Health - Abu Dhabi and Cleveland Clinic will enable further investment in clinical research infrastructure, and deliver evidence that informs clinical practice, ultimately shaping the future of patient care across conditions that are the biggest public health threats, both locally and globally." The collaboration also aims to generate locally relevant evidence, drawing on Abu Dhabi's population-scale health and genomics data to help address the historical underrepresentation of regional populations in pharmaceutical research. The proposed studies will support the development of local investigators and research professionals, while creating opportunities for eligible patients to participate in international clinical research, subject to study approvals and enrolment criteria.

Nojoud Radwan takes on Senior Marketing Lead - GCC role at WHOOP. Radwan was earlier with adidas as Senior Marketing Manager in Saudi Arabia. WHOOP has appointed Nojoud Radwan as Senior Marketing Lead - GCC, following her stint at adidas, where she led marketing strategy in Saudi Arabia. At adidas, she served as Senior Marketing Manager from August 2024 to August 2026, overseeing integrated marketing across digital, retail and influencer channels. Her responsibilities included localising global campaigns for Saudi Arabia, aligning brand narratives with local culture and youth trends, and driving creator-led activations. Before adidas, Radwan spent over six years at Nestlé in roles spanning digital marketing, social media and influencer strategy. As Digital Marketing Manager for Nestlé Purina Petcare and Nestlé Health Science from July 2023 to May 2024, she led regional digital strategy across 19 markets, focusing on e-commerce adoption, performance marketing and brand consistency. Radwan began her tenure at The Coca-Cola Company in September 2013 as Assistant Brand Manager.